Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 260 publications
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: June 22, 2026
The clinical landscape of HIF2α inhibitors in oncology.
Journal: Nature reviews. Clinical oncology
Published: March 23, 2026
Multidisciplinary clinics in cancer-models, metrics, and meaning: a review.
Journal: The oncologist
Published: January 26, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 19, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: January 15, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 14, 2025
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
Journal: CA: a cancer journal for clinicians
Published: September 15, 2025
How can we increase the value of clinical trials with immunotherapy?
Journal: Journal for immunotherapy of cancer
Published: August 15, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.
Journal: Journal for immunotherapy of cancer
Published: August 11, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.
Journal: JCO oncology practice
Published: July 14, 2025
Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2025
Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial.
Journal: Journal for immunotherapy of cancer
Published: July 01, 2025
Last Updated: 09/26/2026